•  
  •  
 

Corresponding Author

Skala Mamand Jawhar

Authors ORCID

0000-0001-6245-0320

Document Type

Research Article

Abstract

The latest anti-diabetic medication sodium-glucose co-transporter inhibitor along with the lowering of blood glucose has a cardioprotective and reno-protective effect, it has the ability to reduce the development of heart failure and decrease hospitalization in heart failure subjects with and without diabetes. This study was conducted to evaluate the effect of sodium-glucose co-transporter inhibitor dapagliflozin alone and in combination with eplerenone on the aldosterone hormone in the treatment of rats with experimentally induced heart failure

Keywords

dapagliflozin, eplerenone, heart failure, aldosterone, neurohormonal change.

Publication Date

2-1-2023

Included in

Life Sciences Commons

Share

COinS